Rituximab and hyaluronidase human, recombinant Subcutaneous and Sirturo Tablets

• Generic Name: hyaluronidase / rituximab
• Dosage Forms: n.a.
• Other Brand Names: Rituxan Hycela

Rituximab and hyaluronidase human, recombinant combination injection is used alone or together with other cancer medicines to treat follicular lymphoma and chronic lymphocytic leukemia (CLL). It is also used together with other medicines to treat diffuse large B-cell lymphoma (DLBCL) in people who have not received previous treatment.

Rituximab and hyaluronidase human, recombinant combination injection is an antineoplastic agent (cancer medicine). It interferes with the growth of cancer cells, which are eventually destroyed by the body.

Rituximab and hyaluronidase human, recombinant is to be given only by or under the direct supervision of your doctor.

• Generic Name: bedaquiline
• Dosage Forms: tablet
• Other Brand Names: Sirturo

Treatment of pulmonary multidrug-resistant tuberculosis (i.e., caused by Mycobacterium tuberculosis resistant to isoniazid and rifampin) in conjunction with other antituberculosis agents.

Designated an orphan drug by FDA for use in treatment of active tuberculosis.

Use only when an effective treatment regimen for multidrug-resistant tuberculosis cannot otherwise be provided.

Safety and efficacy for treatment of drug-susceptible tuberculosis, extrapulmonary (e.g., CNS) tuberculosis, or latent tuberculosis infection not established; use not recommended.

Safety and efficacy for treatment of infections caused by nontuberculous mycobacteria (NTM) not established; use not recommended.

Patients with multidrug-resistant tuberculosis are at high risk for treatment failure and acquisition of further drug resistance. ATS, CDC, and IDSA recommend that such patients be referred to or that consultation be obtained from a specialized treatment center as identified by local or state health departments or the CDC.